Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking.... Interesting. Hopefully this pans out for late buyers
Only up !!!
There are some GREAT companies out, what are your guys favorites?
Great price action here!
Looking like it's heating up for an end-of-day run!
$SPRN
Stop spamming
$SPRN
Yeah, I agree with that.
All in preperation and keeping your eyes open haha!
$SPRN
Yeah, potentially could be a nice grab if this goes lower.
IMO I think this could go much higher than the current...
$SPRN
SPRN up +25% in first 10 min of trading
$$
Looks like SPRN just shot to +25% in the first 10 min........
$$$
SPRN +25% in 10 mins, 1M share vol
+25%SPRN up to +1M in volume in first 10 mins...
Looking like a solid start to the day, folks!
Right on market open, nice volume picking up
$SPRN
Ahaha, Cha-Ching ;)
Always looking for speculative plays
Market Value1 $2,944,143 a/o Mar 01, 2017
Authorized Shares 1,500,000,000 a/o Mar 23, 2016
Outstanding Shares 439,424,393 a/o Nov 20, 2015
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 366,578,284 a/o Nov 20, 2015
Par Value No Par Value
TAKE NOTE THE DATES
THESE MAY NOT HAVE BEEN UPDATED
It's how they profit
Let's see some nice returns for you!!!!
You only lose money when you sell, right?
Comeback kid!!
$$
LOVE WATCHING LONG!
Most people are in things for short term.
Change your way of thinking 'long-term', thats called planning.
Always do your DD!
$$
Then maybe a $10,000 investment wouldn't be a bad idea for the risk of x2 + more (possibly) after buyout
Too heavy in other things and not ready to hold another speculative investment.
$$
For now, just a waiting game!
Bull vs Bear
And with this, I think the Bulls will win. I'm BEARISH on this, but only due to the little knowledge I have with this company.
I'll do some more DD and see what I can find.
BULLISH with the idea of dropping some cash into this for the short term, but already in other things that are speculative
Let me know how it turns out for you!! ;)
$$
Waiting for it aswell.
Dont chase bottom! ;)
Need some solid fundamentals, I'll be watching what happens here in the short term.
Looking like a solid growth though, definitely a great idea.
Like I mentioned in my previous post
This could be a good time to get in for a quick return.
I'm more based on solid fundamentals, not PR fundamentals.
BUT, a lot of people base their buy decisions off of news and "Emotion", so....
If the NEWS is great, the DAY will be great.
Time for profits to the bulls
$$
Pretty GOOD!
Cheers to the Bulls
Looking forward to that then.
For anyone wanting a quick return,this could be the time to do so.
Should.
We'll see what happens, PR's aren't really anything other than the idea of what is to come, or should come.
I'll need to see some filings Haha!
Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today that it received the CPNP notification number required to commercialize Zestra® in all 28 member countries of the European Union.
“We are pleased to expand the commercialization market for Zestra® to the second largest market in the world and believe this will enhance our partnering discussions in EU member countries and eventually expand our sales into this region,” said Innovus Pharma CEO, Dr. Bassam Damaj.
Zestra® is currently exclusively partnered with Orimed Pharma in Canada, Sothema Labs for the Middle East and North Africa, Elis Pharma in Turkey and certain select markets, Oz Biogenics for Myanmar and Vietnam, Biotask in Malaysia, J&H in South Korea and non-exclusively to DanaLife in the alternative markets in select European countries and to PT Laras Bumi Resources, LTD in Hong Kong.
Zestra® is currently approved to be marketed and sold in 34 countries worldwide including the United States, Canada, Europe, India, Hong Kong, the United Arab Emirates (“UAE”), the United Kingdom, Morocco, and South Korea. In addition to the United States, the largest market for Zestra®, Innovus Pharma currently generates Zestra® revenues from the following markets: Canada, Morocco, certain European countries and Hong Kong.
About Zestra® and FSI/AD
Zestra® is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. To date, to Innovus Pharma’s knowledge, no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity.
Approximately 43% of women in the United States age 18 to 59, or 50 million, experience some form of Female Sexual Dysfunction (FSD) according to a published study. (Laumann, E.O. et al. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA, Feb. 10, 1999. vol. 281, No. 6.537-542). The worldwide FSD market is estimated to be more than $500 million per year. For more information on Zestra® visit www.zestra.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sale of the Zestra® product in Europe, the sale of other of the Company’s products, projected online subscribers, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170302005422/en/
Copyright © 2017 Businesswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
NOTHING TO WORRY ABOUT!
LAMPEN RICHARD
Officer
Option Exercise at $0.35 - $0.35 per share. Direct 35,000 Aug 28, 2016 100,000
LAMPEN RICHARD
Officer
Option Exercise at $0.35 - $0.35 per share. Direct 35,000 Jul 27, 2016 100,000
LAMPEN RICHARD
Officer
Purchase at $0.75 - $0.75 per share. Direct 13,000 Jul 4, 2016 17,650
SMALL ALFRED
Officer
Purchase at $0.78 - $0.78 per share. Direct 11,000 Jun 29, 2016 14,000
LAMPEN RICHARD
Officer
Purchase at $0.75 - $0.75 per share. Direct 38,000 Jun 28, 2016 50,000
LAMPEN RICHARD
Officer
Purchase at $0.74 - $0.74 per share. Direct 54,000 Jun 27, 2016 72,300
LAMPEN RICHARD
Officer
Purchase at $0.71 - $0.71 per share. Direct 85,000 Jun 26, 2016 120,000
LAMPEN RICHARD
Officer
Purchase at $0.72 - $0.72 per share. Direct 15,000 Jun 23, 2016 20,200
LAMPEN RICHARD
Officer
Purchase at $0.81 - $0.81 per share. Direct 8,100 May 19, 2016 10,000
LAMPEN RICHARD
Officer
Purchase at $0.89 - $0.89 per share. Direct 8,900 Apr 24, 2016 10,000
LAMPEN RICHARD
Officer
Purchase at $0.85 - $0.85 per share. Direct 7,225 Apr 19, 2016 8,500
LAMPEN RICHARD
Officer
Purchase at $0.89 - $0.89 per share. Direct 8,900 Apr 13, 2016 10,000
LAMPEN RICHARD
Officer
Purchase at $0.88 - $0.88 per share. Direct 8,800 Apr 11, 2016 10,000
LAMPEN RICHARD
Officer
Purchase at $0.85 - $0.85 per share. Direct 6,035 Mar 28, 2016 7,100
Thanks Pete! Appreciate your contribution! :)
:D
OHHHH THAT would be SO nice.
Sitting...Waiting...Watching...
Well... It's been a long time coming, right?
see what happens..
Congrats on being able to look at a chart and determine its going lower, even though you claim you "Don't read charts"
Do you have any info that is useful, or is everything you post redundant
unless you are.
I think this might crumble
I will, thank you LOL!
look at short term movement.
never said it was a good company.
Lets see how they par up!
Starting to get exciting ! ;)
YEAH!?
MACROECO BRO
it all has an impact on everything.
EVERYTHING.
play the news, you own the markets.
people are emotional
just waiting for more news. lets see what it brings
;)
I hear Gegi rolls too.